All News
Infections in pre-RA: a cause or a consequence?
Rheumatoid arthritis is known to be associated with a higher risk of infections. In abstract 0535, Porter and colleagues have assessed infection rates in the pre-RA and early RA phases as defined by antibiotics prescription and hospital admissions with an infection main diagnostic code in the UK National database.
Read Article
What do you look for on temporal artery examination in GCA assessment?
tenderness: minimally useful
reduced/absent pulse or thickening: quite good if there, nearly as good as halo
Good examination is powerful, if you're doing it right!
ABST0483 Salvarani group #ACR22 @RheumNow https://t.co/B3qvSW68at
David Liew drdavidliew ( View Tweet)
Abs 0406 demonstrates stronger relationship between disease activity (using BASFI and BASDAI) and quality of life in men w/ axSpA than women. IMO, it also demonstrates need for better assessment tools for women! #ACR22 @RheumNow https://t.co/B44ZixyeAJ https://t.co/lMzpsGcsFM
Dr. Rachel Tate uptoTate ( View Tweet)
Abs0399 ASAS recs for requesting/reporting imaging in suspected AxSpA pts key takeaway: communication!
Rheum provides pertinent hx (trauma, childbirth, pain location, duration, etc), DDx
Rads summarize hx & give pertinent +/- exam findings
#ACR22 @RheumNow https://t.co/Ucr8B5xfGA https://t.co/F6g15dQhj1
Dr. Rachel Tate uptoTate ( View Tweet)
2022 ASAS-EULAR Recommendations of AxSpA management
1) NSAIDs still first line
2) Analgesics/opioids contraindicated
3) TNFi, IL-17i first line bDMARDs, followed by JAKinibs
4) Tapering but not discontinuation of bDMARDs in sustained remission
Abs#0542 @RheumNow #ACR22 https://t.co/ffaN2fMc3v
Robert B Chao, MD doctorRBC ( View Tweet)
Saturday: ACR 2022 Daily Recap https://t.co/3WGcxsEtOj
Dr. John Cush RheumNow ( View Tweet)
Emerging and exciting treatments in RA: #ACR22 preview
https://t.co/5JtblF9MxE https://t.co/oYSiLguLkJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Are DNA methylation marks the new seronegative RA biomarkers?
Riskedal et al. propose a new model based on whole-blood DNAm profiles
Sens 90%, Spe 88%, Accuracy 89% for classification of RA
Accuracy RA Sero+ 100%, RA Sero- 75%
https://t.co/3occAQPZ1u Abs#0531 #ACR22 @Rheumnow https://t.co/QXhMxyWC8g
Aurelie Najm AurelieRheumo ( View Tweet)
Terrier @TerrierBen . Pooled analysis of MAINRITSAN trials. For major relapse at 84 months RTX>AZA HR 2.5. RTX fixed-dose>tailored HR 3. RTX 18 vs 36 months equal HR 1.2 (although 78% vs 70% relapse free). @RheumNow #ACR22 Abstr#0527 https://t.co/IWQmcGeRiW
Richard Conway RichardPAConway ( View Tweet)
So great to be in person for higher learning in #rheumatology #ACR22 @RheumNow also the onliners are welcomed https://t.co/JIcyV7v1Ws
Janet Pope Janetbirdope ( View Tweet)
Khanna @sclerodermaUM. SLS-III MMF+Pirfenidone vs MMF alone in SSc-ILD. Underpowered due to COVID (51 vs 150). No difference FVC 18 months ?more rapid improvement in combo. Better HRCT, PROs in combination. Need another study! @RheumNow #ACR22 Abstr#0520 https://t.co/K2Ne6PSHkS https://t.co/P6A7OJpzCf
Richard Conway RichardPAConway ( View Tweet)
#Abstr 0542 ASAS EULAR Recommendations for Management of axSpA
'Absence of response to treatment should prompt re-evaluation of the diagnosis and consideration of the presence of comorbidities.'
@RheumNow #ACR22
Akhil Sood MD AkhilSoodMD ( View Tweet)
18mo data of ARIAA study (6mo ABA in pre-RA):
12mo after discontinuation
Progression to RA ABA 35% vs PBO 57% p=0.008
Improvement in synovitis, osteitis & tenosynovitis ABA 57% vs. 29% PBO
Enough to move into clinical application?
https://t.co/2CDN9M31mB
Abs#0530 #ACR22 @Rheumnow https://t.co/R54AokGSiK
Aurelie Najm AurelieRheumo ( View Tweet)
Jayne et al. ADVOCATE avacopan trial sub-analysis looking at patients eGFR<=20. Significantly better reduction albuminuria and increase eGFR. Numerically better recovery, lower GC, less infection @RheumNow #ACR22 Abstr#0525 https://t.co/v4ffiqfsyt https://t.co/9pK0Pn6IOj
Richard Conway RichardPAConway ( View Tweet)
🔎Look! Urinary biomarkers vs. UPCR in tx response of #lupus nephritis by Dr @andreafava et al
🦋A decline in several urinary BMs at 3 mos outperformed UPCR in predicting the 1 yr response.
Urinary BMs as surrogate endpts in trials?🤔#ACR22 @RheumNow ABST0536 https://t.co/kMWmsK8mnO
sheila RHEUMarampa ( View Tweet)
@GuyKatzMD @zach_wallace_md et al. Hypocomplementemia seen in 30% IgG4-RD. More organs involved (mean 4.3 vs 2.9). More likely to have serum IgG4 above ULN (89%vs74%) and 5XULN (52%vs28%) @rheumnow #ACR22 Abstr#0144 https://t.co/bVRTuh3dsU https://t.co/3SHEbg2tbR
Richard Conway RichardPAConway ( View Tweet)
Sanchez-Bilbao et al. IV vs SC tocilizumab in 471 GCA patients. No differences in sustained remission or glucocorticoid-sparing. Numerically more AEs in IV but this due to longer follow up, no difference when corrected @rheumnow #ACR22 Abstr#0146 https://t.co/EB2RMYdzAr https://t.co/4xIMH1PIt3
Richard Conway RichardPAConway ( View Tweet)
Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher creatinine. DAH more likely to die at 30 days and 1 year than those without DAH @RheumNow #ACR22 Abstr#0526 https://t.co/XGYHvDkVeA https://t.co/IEOcQHEQ3e
Richard Conway RichardPAConway ( View Tweet)
Normal weight PsA pts had numerically better PsAID and PGA scores than obese PsA pts when treated with SEC. SEC was effective in all BMI subgroups. Abs 0395 #ACR22 @RheumNow https://t.co/oBSsuJKRem https://t.co/BhybOk76Gr
Dr. Rachel Tate uptoTate ( View Tweet)
Werth et al. Lenabasum phase 3 trial indermatomyositis. Primary endpoint (TIS week 28) not met. Subgroup analysis suggest small effect on muscle and modest effect on skin disease @rheumnow #ACR22 Abstr#0173 https://t.co/qhL2PcTcHV https://t.co/uR8Bg5awiK
Richard Conway RichardPAConway ( View Tweet)
